Pharmaceutical manufacturers with United States Food and Drug Administration-approved prescription drugs sold in or into Texas with any prescription drugs costing $100 or more for a one-month supply as outlined in Chapter 441, §441.002 (c) are required to submit a manufacturer activity report.
The manufacturer activity report is a list of every drug that has lost patent exclusivity and/or received U.S. FDA approval in the last three calendar years. It also includes the manufacturer’s R&D costs.
Last updated: 08/12/2021
| Manufacturer | Change type | Change year | NDC 11 | Trade Name | Generic Name | R and D cost |
|---|---|---|---|---|---|---|
| ACADIA Pharmaceuticals Inc. | A | 2016 | 63090034030 | NUPLAZID | pimavanserin | $240,385,000 |
| ACADIA Pharmaceuticals Inc. | A | 2016 | 63090010030 | NUPLAZID | pimavanserin | $240,385,000 |
| Alexion | 2020 | 25682001001 | STRENSIQ | asfotase alfa | $1,010,600,000 | |
| Alexion | 2020 | 69583010201 | ANDEXXA | coagulation factor Xa,inactivated-zhzo (recombinant) | $1,010,600,000 | |
| Alexion | 2020 | 25682002801 | ULTOMIRIS | ravulizumab-cwvz | $1,010,600,000 | |
| Alexion | 2020 | 25682002501 | ULTOMIRIS | ravulizumab-cwvz | $1,010,600,000 | |
| Alexion Pharmaceuticals | 2020 | 25682001912 | STRENSIQ | asfotase alfa | $1,010,600,000 | |
| Alexion Pharmaceuticals | 2020 | 25682001612 | STRENSIQ | asfotase alfa | $1,010,600,000 | |
| Alexion Pharmaceuticals | 2020 | 25682001312 | STRENSIQ | asfotase alfa | $1,010,600,000 | |
| Alexion Pharmaceuticals | 2020 | 25682000701 | KANUMA | sebelipase alfa | $1,010,600,000 | |
| Alexion Pharmaceuticals | 2020 | 25682000101 | SOLIRIS | eculizumab | $1,010,600,000 | |
| Alexion Pharmaceuticals | 2020 | 25682002201 | ULTOMIRIS | ravulizumab-cwvz | $1,010,600,000 | |
| Avanir Pharmaceuticals, Inc. | 00000000000 | Not applicable | Not applicable | $2,053,177,926 | ||
| B. Braun Medical Inc. | A | 2019 | 00264450005 | Plenamine | 15% Amino Acids Injection | $55,260,000 |
| B. Braun Medical Inc. | A | 2019 | 00264937988 | Bupivacaine HCl 0.75% in Dextrose 8.25% Injection USP | Bupivacaine HCl 0.75% in Dextrose 8.25% Injection USP | $55,260,000 |